Edwards TAVR

Changing lives starts with outstanding outcomes. SAPIEN 3 TAVR: a design proven to last. See the 7- and 10-year data: ow.ly/FCPJ50YIZtp ⚠️ Important Safety Info: ow.ly/RSnj50YIZtq

The conference is over. The data are becoming clear: Severe aortic stenosis demands critical action. To further examine why “Every Minute Matters,” visit our site to explore the data: ow.ly/PToU50YznuA

When it comes to severe aortic stenosis, prompt action is LIFESAVING action. Find out more when you join us for the #ACC26 symposium on emerging data and evolving guidelines. Reserve your seat today: ow.ly/3UIF50YlgFM. Visit us at the Edwards booth.

It’s almost time for #ACC26. Find out why Every Minute Matters at this year’s symposium. Reserve your seat now: ow.ly/5B1z50YlgrO. Be sure to visit the Edwards booth. There will be data to explore and coffee to enjoy.

SAPIEN 3 TAVR demonstrates excellent valve durability in intermediate-risk patients out to 10 years. Watch the clinical discussions: ow.ly/eizm50XAVgi ⚠️ Important Safety Info: ow.ly/rARc50XAU05

With a low frame height, the SAPIEN 3 Ultra RESILIA valve preserves the clearest path for future interventions. For severe aortic stenosis patients, Edwards SAPIEN 3 TAVR is the optimal choice. Watch videos: ow.ly/62YI50YoRml ⚠️Important Safety Info: ow.ly/is7E50YoRmk

With excellent long-term durability and valve performance similar to SAVR out to 7 and 10 years, Edwards SAPIEN 3 TAVR delivers lasting outcomes for severe AS patients regardless of symptoms. Watch videos: ow.ly/GEn550YlFGO ⚠️Important Safety Info: ow.ly/e8TT50YlFGP

🎥 Streamline your #TAVR pathway with this new video series from @Edwards_TAVR Discover how timely care improves triage, staffing, discharge & cost outcomes to optimize your approach: hubs.li/Q03_NJ2h0

Edwards SAPIEN 3 TAVR demonstrated excellent long-term durability and valve performance similar to SAVR. Watch Dr. Mack’s presentation from TCT 2025: ow.ly/Xonh50YhROk ⚠️Important Safety Info: ow.ly/gfKw50YhRlB

Could your severe AS patients be at risk for sudden and deadly symptom onset? See @FaRodriguezMD and @drrahulpsharma discuss patient cases that underscore the unpredictable nature of #severeaorticstenosis —reinforcing the crucial need for prompt referral: ow.ly/EXzB50Y29hP

“Many of these patients, if we wait to the point they’re severe and symptomatic—and overtly symptomatic…we may have waited too long.” – @DocStrom Hear from your peers on the evolution of AS referral on @TCTMD's podcast, Heart Valve Matters: ow.ly/WKuX50XUggC

Are misperceptions slowing your decision-making in #severeaorticstenosis management? Watch below as interventional cardiologist Dr Pop advises how to handle common myths, including not having enough time to see patients and being uncertain of whether treatment therapy is needed.

The data really bore out in this population that treating them upfront...is really a best practice...So that’s what I recommended for my own dad.” Hear what happens when severe AS hits close to home for one card on @TCTMD's podcast Heart Valve Matters: ow.ly/CRz950XLMB0

EARLY TAVR™ trial, the first RCT comparing TAVR w/ watchful waiting in asymp severe AS pts, included a sub-analysis assessing the impact of LV health. Data confirmed a consistent benefit with prompt TAVR across baseline LV health categories. See the data: ow.ly/ok1450XK4hO

~40% of patients w/ severe aortic stenosis (AS) presented w/ advanced signs & symptoms at the time of AVR conversion (Généreux NEJM 2025). Watch below as echocardiologist @DocStrom discusses the rapid & unpredictable nature of severe AS & the lifesaving impact of prompt referral.

When's the right time to talk with aortic stenosis (AS) patients about treatment options and goals? Patients are ready earlier than HCPs expect. I’m collaborating with @EdwardsLifeSci on ways the Informed Decision Guide can help you start the conversation. ow.ly/KZgE50WUfSx

ICYMI at TCT 2025: results from a retrospective analysis of 1100+ severe AS patients found that prompt referral and intervention prior to symptom onset may be associated with significant cost and healthcare resource utilization benefits. Explore the data: ow.ly/UU8150XAUhL

From TCT 2025: a real world-study of 4000+ severe AS patients found that elective TAVR ≤90 days of diagnosis significantly decreased the risk of death (50%) and HF hospitalization (59%) + reduced the risk of stroke by 25% vs delayed TAVR.* See the data: ow.ly/gWeU50XB16U

"[Severe AS is]...unfortunately always progressive, and—untreated—is always fatal...Why wait for trouble?" Hear more from clinical cardiologists Michael Mack and Allan Schwartz on @TCTMD's podcast, Heart Valve Matters: ow.ly/rLTE50XxS7c